Mylan Company Profile (NASDAQ:MYL)

About Mylan

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: MYL
  • CUSIP: 62853010
Key Metrics:
  • Previous Close: $37.02
  • 50 Day Moving Average: $39.42
  • 200 Day Moving Average: $43.59
  • 52-Week Range: $534,911,000.00 - $35.58
  • Trailing P/E Ratio: 23.92
  • Foreward P/E Ratio: 6.61
  • P/E Growth: 0.59
  • Market Cap: $20.22B
  • Outstanding Shares: 534,911,000
  • Beta: 1.14
  • Net Margins: 8.11%
  • Return on Equity: 23.22%
  • Return on Assets: 9.82%
  • Debt-to-Equity Ratio: 1.24%
  • Current Ratio: 3.23%
  • Quick Ratio: 2.65%
Additional Links:
Companies Related to Mylan:

Analyst Ratings

Consensus Ratings for Mylan (NASDAQ:MYL) (?)
Ratings Breakdown: 8 Hold Ratings, 8 Buy Ratings, 2 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $53.63 (44.85% upside)

Analysts' Ratings History for Mylan (NASDAQ:MYL)
DateFirmActionRatingPrice TargetDetails
10/10/2016JPMorgan Chase & Co.Set Price TargetBuy$52.00View Rating Details
10/10/2016BTIG ResearchReiterated RatingBuy$55.00View Rating Details
10/10/2016RBC Capital MarketsReiterated RatingSector Perform$48.00View Rating Details
10/10/2016Raymond James Financial Inc.UpgradeMarket Perform -> Strong-Buy$57.00View Rating Details
10/1/2016Leerink SwannSet Price TargetBuy$55.00 -> $45.00View Rating Details
10/1/2016Wells Fargo & Co.Set Price TargetHold$44.00View Rating Details
9/22/2016ArgusSet Price TargetBuy$55.00View Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00View Rating Details
9/23/2016Deutsche Bank AGSet Price TargetBuy$60.00 -> $58.00View Rating Details
9/6/2016Royal Bank Of CanadaLower Price TargetSector Perform$52.00 -> $48.00View Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00View Rating Details
8/25/2016Goldman Sachs Group Inc.Reiterated RatingConviction-Buy$60.00View Rating Details
8/24/2016Bank of America Corp.Reiterated RatingBuy$70.00View Rating Details
7/12/2016Morgan StanleyReiterated RatingHoldView Rating Details
2/11/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
2/11/2016GuggenheimReiterated RatingNeutralView Rating Details
2/11/2016Cowen and CompanyLower Price TargetMarket Perform$65.00 -> $55.00View Rating Details
11/16/2015BMO Capital MarketsLower Price TargetMarket Perform$46.00View Rating Details
9/21/2015Barclays PLCInitiated CoverageEqual Weight$57.00View Rating Details
8/26/2015Standpoint ResearchInitiated CoverageBuy$70.00View Rating Details
8/12/2015SusquehannaLower Price TargetPositive$85.00 -> $68.00View Rating Details
6/18/2015B. RileyInitiated CoverageBuy$85.00 -> $71.23View Rating Details
4/22/2015CRT CapitalBoost Price TargetBuy$68.00 -> $87.00View Rating Details
(Data available from 10/24/2014 forward)


Earnings History for Mylan (NASDAQ:MYL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.49 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.69$0.70$1.87 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.73$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.68$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.69 billion$1.63 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mylan (NASDAQ:MYL)
Current Year EPS Consensus Estimate: $4.81 EPS
Next Year EPS Consensus Estimate: $5.6 EPS


Dividend History for Mylan (NASDAQ:MYL)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Mylan (NASDAQ:MYL)
Insider Ownership Percentage: 0.71%
Institutional Ownership Percentage: 60.35%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.50View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.30View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.00View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.00View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.80View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.32View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.00View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.10View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.21View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.04View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.00View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.00View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.50View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.00View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.95View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.00View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.32View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Mylan (NASDAQ:MYL)
DateHeadline logoEpiPen Shows A Path To Solve The Bigger Drug Pricing Challenge (NASDAQ:MYL) - October 24 at 11:46 AM logoDeferred Tax Assets Of Mylan Inc. (NASDAQ:MYL) At $250.1 - (NASDAQ:MYL) - October 23 at 6:04 PM
News IconMylan NV (NASDAQ:MYL) Investor Alert: Lawsuit alleges False and Misleading Statements (NASDAQ:MYL) - October 22 at 10:23 AM logoAAI urges court to reconsider dismissal of Mylan product-hopping case (NASDAQ:MYL) - October 22 at 10:23 AM logoMYLAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mylan N.V. - MYL (NASDAQ:MYL) - October 22 at 10:23 AM logoSenator Warren Says Mylan Settlement With DOJ ‘Shamefully Weak’ (NASDAQ:MYL) - October 21 at 6:21 PM logoElizabeth Warren just torched the DOJ in a letter — and may have called out a lie by the maker of EpiPen (NASDAQ:MYL) - October 21 at 6:21 PM logoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mylan N.V. of Class Action Lawsuit and Upcoming Deadline - MYL (NASDAQ:MYL) - October 21 at 6:21 PM logoThe maker of EpiPen won't answer this yes or no question about its DOJ settlement (NASDAQ:MYL) - October 21 at 6:21 PM
News IconWhat are Research Firms Saying About Mylan Inc. (NASDAQ:MYL)? - CSZ News (NASDAQ:MYL) - October 21 at 9:45 AM logoStock Rating Of Mylan Inc. (NASDAQ:MYL) At 1.91 - Stocks Daily (NASDAQ:MYL) - October 21 at 9:45 AM logoMYL NOTICE: Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline in Class Action Filed by Firm - MYL - Business Wire (press release) (NASDAQ:MYL) - October 21 at 9:45 AM logoBest And Worst Biotech ETFs Of 2016 Tell A Tale About This Industry (NASDAQ:MYL) - October 21 at 9:45 AM
News IconBlog Coverage COPD Drug Revefenacin Jointly Being Developed by Theravance Biopharma and Mylan Shows Promise (NASDAQ:MYL) - October 21 at 9:45 AM logoMylan, Theravance announce successful phase III studies for COPD drug (NASDAQ:MYL) - October 20 at 6:40 PM logoTheravance Biopharma and Mylan Announce Positive Results from Two Pivotal ... (NASDAQ:MYL) - October 20 at 12:02 PM logoMylan (MYL), Theravance Biopharma(TBPH) Announce Positive Data from Two Revefenacin Phase 3s as COPD Treatment (NASDAQ:MYL) - October 20 at 12:02 PM logoMylan: Revefenacin Meets Primary Efficacy Endpoint, Shown To Be Well-Tolerated (NASDAQ:MYL) - October 20 at 12:02 PM logoTheravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin … (NASDAQ:MYL) - October 20 at 12:02 PM logoTheravance Biopharma and Mylan Announce Positive Results from Two Pivotal Phase 3 Studies of Revefenacin (TD-4208) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) (NASDAQ:MYL) - October 20 at 12:02 PM logoHeadline Risk Is Still Poison For These Stocks (NASDAQ:MYL) - October 20 at 12:02 PM logoRoche sees no 'fundamental change' in price pressure after U.S. vote (NASDAQ:MYL) - October 20 at 12:02 PM logoSen. Blumenthal: Mylan DOJ Settlement a 'Sweetheart' Deal (NASDAQ:MYL) - October 19 at 6:39 PM logoBlumenthal Says Mylan’s Settlement With DOJ a ‘Sweetheart Deal’ (NASDAQ:MYL) - October 19 at 6:39 PM logoMylan’s Settlement With DOJ Not Tough Enough, Senator Says (NASDAQ:MYL) - October 19 at 6:39 PM logoMYL NOTICE: Rosen Law Firm Reminds Mylan N.V. Investors of Important Deadline in Class Action Filed by Firm - MYL (NASDAQ:MYL) - October 19 at 6:39 PM logoAbbott Posts Slight Q3 Beat, Narrows Outlook - Benzinga (NASDAQ:MYL) - October 19 at 11:20 AM logoAbbott Labs Swings to Loss After Booking Charge on Mylan Stake - Wall Street Journal (NASDAQ:MYL) - October 19 at 11:20 AM logoMylan: EpiPen Classification Continues To Plague - Seeking Alpha (NASDAQ:MYL) - October 19 at 11:20 AM logoMylan Has Returned 16.8% Since SmarTrend Recommendation (MYL) (NASDAQ:MYL) - October 18 at 6:12 PM logoMylan's 1,100% Price Hike: EpiPen Lawsuit May Go Nationwide (NASDAQ:MYL) - October 18 at 6:12 PM logoMylan's Price Hike: EpiPen Suit May Go Nationwide (NASDAQ:MYL) - October 18 at 6:11 PM logoAre toxic lakes the cost of cheap drugs? (NASDAQ:MYL) - October 18 at 11:37 AM logoEPS Target Range For Mylan Inc. (NASDAQ:MYL) At $5.23 – $5.83 - (NASDAQ:MYL) - October 17 at 6:12 PM logoSHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Mylan N.V. To Contact Brower Piven Before The Lead Plaintiff Deadline – MYL (NASDAQ:MYL) - October 17 at 6:12 PM logoMylan Inc. (NASDAQ:MYL) Deferred Tax Assets At $250.1 - (NASDAQ:MYL) - October 17 at 11:27 AM logoEPS Target Of Mylan Inc. (NASDAQ:MYL) At $1.53? - Stocks Daily (NASDAQ:MYL) - October 17 at 11:27 AM logoMylan Now Likely An Acquisition Target With 100% Upside Possible ... - Seeking Alpha (NASDAQ:MYL) - October 17 at 11:27 AM logoDrug companies love to say coupons are helping offset rising costs, but new research shows that's not always true (NASDAQ:MYL) - October 17 at 11:27 AM
News IconMylan's $465M EpiPen Settlement Unlikely to End Scrutiny - InsideCounsel (NASDAQ:MYL) - October 16 at 6:04 PM logo[$$] How an executive MBA can signal your next move (NASDAQ:MYL) - October 16 at 6:04 PM
News IconMylan Inc. (NASDAQ:MYL) Updated Analyst Coverage - NewsDen (NASDAQ:MYL) - October 16 at 10:43 AM
News IconSell-side Taking Aim at Shares of Mylan Inc. (NASDAQ:MYL) - CSZ News (NASDAQ:MYL) - October 15 at 5:56 PM
News IconJerry Osteryoung: Mylan demonstrates what is wrong with big business - Bradenton Herald (blog) (NASDAQ:MYL) - October 15 at 5:56 PM logoMYLAN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mylan N.V. – MYL (NASDAQ:MYL) - October 15 at 11:02 AM logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Mylan N.V. (MYL) & Lead Plaintiff Deadline - December 12, 2016 (NASDAQ:MYL) - October 14 at 6:06 PM logoGlancy Prongay & Murray LLP Commences Investigation on Behalf of Mylan N.V. Investors (NASDAQ:MYL) - October 14 at 6:06 PM logoForget Netflix: Will YouTube, Twitter, and Facebook Kill TV? (NASDAQ:MYL) - October 14 at 6:06 PM logoThe Zacks Friday Finish Line Highlights: Mylan, Twitter, Tesla & SolarCity, YouTube (NASDAQ:MYL) - October 14 at 6:06 PM
News IconJerry Osteryoung: Mylan demonstrates what is wrong with big business (NASDAQ:MYL) - October 13 at 6:25 PM


Mylan (NASDAQ:MYL) Chart for Monday, October, 24, 2016

Last Updated on 10/24/2016 by Staff